Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Baxter International    BAX

BAXTER INTERNATIONAL (BAX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/12/2018 09/13/2018 09/14/2018 09/17/2018 09/18/2018 Date
76.08(c) 77.13(c) 77.69(c) 77.04(c) 77.24(c) Last
2 351 937 2 903 529 2 305 009 2 657 169 2 228 233 Volume
+0.28% +1.38% +0.73% -0.84% +0.26% Change
More quotes
Financials (USD)
Sales 2018 11 204 M
EBIT 2018 1 924 M
Net income 2018 1 491 M
Debt 2018 -
Yield 2018 0,90%
Sales 2019 11 696 M
EBIT 2019 2 211 M
Net income 2019 1 699 M
Finance 2019 396 M
Yield 2019 1,04%
P/E ratio 2018 29,78
P/E ratio 2019 25,10
EV / Sales2018 3,68x
EV / Sales2019 3,49x
Capitalization 41 267 M
More Financials
Company
Baxter International, Inc. provides a broad portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug... 
More about the company
Surperformance© ratings of Baxter International
Trading Rating : Investor Rating :
More Ratings
Latest news on BAXTER INTERNATIONAL
09/17BAXTER INTERNATIONAL : Named to Dow Jones Sustainability Index for 19th Consecut..
AQ
09/13BAXTER INTERNATIONAL : Announces U.S. FDA Clearance of New Bone Graft Substitute..
AQ
09/13BAXTER INTERNATIONAL : An Application for the Trademark "EQUILIBRIA" Has Been Fi..
AQ
09/13BAXTER INTERNATIONAL : Unveils Olimel 7.6% High Protein Parenteral Nutrition For..
AQ
09/13BAXTER INTERNATIONAL : Named to Dow Jones Sustainability Index for 19th Consecut..
BU
09/10EXCLUSIVE - CAMPBELL SOUP STEPS UP C : sources
RE
09/10EXCLUSIVE : Campbell Soup steps up CEO search, COO a contender - sources
RE
09/10BAXTER INTERNATIONAL : FDA approves Baxters Actifuse Flow bone graft substitute
AQ
09/06BAXTER INTERNATIONAL : Unveils Olimel 7.6% High Protein Nutrition Formulation at..
AQ
09/06BAXTER INTERNATIONAL : Gets FDA Approval for Actifuse Flow Bone Graft Substitute
DJ
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
09/13Smiths and ICU Medical healthcare merger talks collapse
RE
09/11STRYKER : to Buy Invuity for About $190 Million
DJ
09/07THERMO FISHER SCIENTIFIC : to Buy Becton Dickinson's Advanced Bioprocessing Unit..
DJ
09/07THERMO FISHER SCIENTIFIC : to Buy Becton Dickinson's Advanced Bioprocessing Unit
DJ
09/04ICU MEDICAL INCORPORATED : Smiths rebuffs ICU's latest offer for medical divisio..
RE
More sector news : Medical Equipment, Supplies & Distribution - NEC
Latest Tweets
09/17Zack Martin, Sean Lee seem pretty happy
53
09/16$BAX is Bullish above $76.79. Trade near $76.79  
09/14$BAX International Inc. Baxter International Inc. - June 2018 (LTM): Peer Sn.. 
09/12Baxter $BAX leader in healthcare with 20% EPS growth, moving out of weekly co..
2
09/11$BAX UNUSUAL BUYING ..
1
More tweets
Qtime:167
News from SeekingAlpha
09/05Baxter Ventures Invests In Outset Medical For Improved Renal Care Tech 
09/04Baxter unveils Olimel 7.6% high protein parenteral nutrition formulation at t.. 
09/02Tracking George Soros's Portfolio - Q2 2018 Update 
08/24Gritstone Oncology Files For $80 Million U.S. IPO 
08/24BAXTER : Exit Strategy 
Chart BAXTER INTERNATIONAL
Duration : Period :
Baxter International Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAXTER INTERNATIONAL
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 79,6 $
Spread / Average Target 3,1%
EPS Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Executive Vice President
Paul E. Martin Chief Information Officer & Vice President
Sumant Ramachandra Chief Science & Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL19.18%41 160
MEDTRONIC PLC19.98%129 690
ALIGN TECHNOLOGY70.29%30 391
ZIMMER BIOMET HOLDINGS8.10%26 362
HOYA CORPORATION15.69%22 439
TERUMO CORP23.05%21 832